Skip to main content

Table 2 Clinical characteristics of patients in studies included in the meta-analysis

From: Estimates of the effect on hepatic iron of oral deferiprone compared with subcutaneous desferrioxamine for treatment of iron overload in thalassemia major: a systematic review

First Author Number of patients with
hepatic iron information
Treatment & mean dose
(mg/kg/day)
Initial ferritin level,
mean (SD) (μg/L)
Hepatic iron
concentration, Mean (SD)
Measurement
unit
     Initial Final  
Hoffbrand AV 4 DFO 57 10,683 (NA) 76.7 (30.4) 56.9 (42.9) μg/mg dry
Janka GE 2 DFO 103§ 3,294 (1,462)* 26.9 (16.0) 9.9 (5.5) g/kg dry
Aldouri MA 12 DFO 50 5,885 (3,245)* 2945 (900) 857 (435) μg/100 mg dry, chemical
Maurer HS 12 DFO 85§ 3,164 (1,321)* 3,275.5 (1,225.1) 1508.3 (887.3) μg/100 mg dry
Olivieri NF 21 L1 75 3,975 (3,510) 81.9 (51.6) 46.7 (26.4) μmol/g wet
Olivieri NF 37 L1 75 NA L1: 8.9 (1.2) L1: 13.7 (1.2) mg/g dry
   DFO 37   DFO: 6.9 (0.9) DFO: 7.9 (1.3)  
Longo F 52 L1 75 1,897 (NA) 1430 (NA) 2029 (NA) μg/g
Mazza P 20 L1 70 4,495 (2,644) 16.1 (12.4) 20.4 (20.0) mg/g dry
Olivieri NF 18 L1 75 4,455 (3,569) 89.1 (50.8) 65.4 (33.5) μmol/g wet
Tondury P 9 L1 82 2,862 (1,390)** 7.6 (4.4) 8.9 (5.6) mg/g dry
Diav-Citrin O 19 L1 75 3,122 (NA) 14.3 (7.2) 10.0 (6.1) mg/g dry
  1. * Mean for the entire study population; not specific to the subgroup of patients for which hepatic iron information is available.
  2. ** Mean for subgroup of 7 patients.
  3. † Calculated using midpoint of range of total daily dose provided and individual patients' weight estimates derived from gender-specific weight charts.
  4. ‡ Midpoint of range.
  5. § Maximum dose.
  6. ¶ Values read from graph. Scaling error in the original report has been corrected.
  7. DFO Desferrioxamine; L1: deferiprone; NA: not available.